Skip to content

A Retrospective Study on Hospitalized Patients With Community-acquired Pneumonia in China (CAP-China)

Management in Real-life of Patients Hospitalized With Community-acquired Pneumonia in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02489578
Acronym
RSCAP-China
Enrollment
3000
Registered
2015-07-03
Start date
2015-07-31
Completion date
2016-12-31
Last updated
2015-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Pneumonia

Keywords

Community Acquired Pneumonia, health care associated pneumonia

Brief summary

The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and healthcare-associated pneumonia (HCAP) in real life of China .

Detailed description

In China, the data about current management of patients hospitalized with CAP in the real-life setting is not available,type of pneumonia, selection of initial antibiotic, time to clinical stability, antibiotic choice anf modification,clinical outcomes and costs remain unclear. In this study, we will collect comprehensive information on CAP and HCAP management patterns to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China .to analyze microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of patients with CAP (\> and = 65 years, different comorbidities ,risk factors) ,to investigate microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of disease severity with CAP ,to provide the difference on microbiological characteristics,clinical manifestations,antibiotic regimens ,and outcome between patients with CAP and HCAP ,to understand the current situation of antibiotic regimen ,to evaluate influence of different antibiotic regimens on prognosis.

Interventions

OTHERother

retrospective cohort study

Sponsors

Beijing Chao Yang Hospital
CollaboratorOTHER
Beijing Jishuitan Hospital
CollaboratorOTHER
Beijing Luhe Hospital
CollaboratorOTHER
Qingdao Municipal Hospital
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
Beijing Huimin Hospital
CollaboratorUNKNOWN
China-Japan Friendship Hospital
CollaboratorOTHER
Linzi Hospital
CollaboratorUNKNOWN
Second Hospital of Beijing Armed Police Corps
CollaboratorUNKNOWN
Kunming Yan'an Hospital
CollaboratorUNKNOWN
Capital Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \> or = 14 years of age * Patient meets the criteria of community acquired pneumonia * Patient meets the criteria of healthcare-associated pneumonia

Exclusion criteria

* Patients \<14 years of age * Patient meets the criteria of hospital acquired pneumonia * Known active tuberculosis or current treatment for tuberculosis * Non-infectious pulmonary diseases * HIV positive

Design outcomes

Primary

MeasureTime frameDescription
treatment failure at 72h after initiation of antibioticsTime from the first dose use of antibiotics to 72 hourstreatment failure was defined as a change of antibiotics due to worsening signs or symptoms associated with pneumonia
in-hospital treatment failure due to multiple causesTime from date of admission to discharge up to 1 week1)death in hospital;2)change of antibiotics due to worsening signs or symptoms of infection, 3) recurrence, defined as signs or symptoms of infection after completion of therapy requiring re-initiation of antibiotics

Secondary

MeasureTime frameDescription
Duration of intravenous antimicrobial therapy2 weeksTime from the first dose of intravenous antibiotics to date of stop of intravenous antibiotics ,participants will be followed for the duration of hospital stay
Hospital length of stay2 weeksPatients will be asked about hospitalization, date, Patients will be asked about hospitalization, date, participants will be asked about the time of admission and discharge
in-hospital mortality2 weeksTime from date of admission to date of discharge,participants will be followed for the duration of hospital stay

Countries

China

Contacts

Primary ContactBin Cao, MD
caobin_ben@163.com86-010-84206264
Backup ContactLI Gu, MD
guli2013227@foxmail.com.cn86-010-85231514

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026